Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Liabilities: 2012-2025

Historic Total Liabilities for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $216.0 million.

  • Enanta Pharmaceuticals' Total Liabilities fell 12.84% to $216.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.0 million, marking a year-over-year decrease of 12.84%. This contributed to the annual value of $216.0 million for FY2025, which is 12.84% down from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Total Liabilities is $216.0 million, which was down 2.59% from $221.8 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Total Liabilities ranged from a high of $257.4 million in Q2 2023 and a low of $31.7 million during Q1 2021.
  • In the last 3 years, Enanta Pharmaceuticals' Total Liabilities had a median value of $236.8 million in 2024 and averaged $222.3 million.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Total Liabilities declined by 16.92% in 2022 and then soared by 445.34% in 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Total Liabilities (Quarterly) stood at $56.2 million in 2021, then fell by 16.92% to $46.7 million in 2022, then spiked by 406.70% to $236.6 million in 2023, then grew by 0.09% to $236.8 million in 2024, then fell by 12.84% to $216.0 million in 2025.
  • Its Total Liabilities was $216.0 million in Q3 2025, compared to $221.8 million in Q2 2025 and $229.5 million in Q1 2025.